```html

Quilted Airway Disease (Rare) – A Complete Patient Guide

Overview

Quilted airway disease (QAD) is an extremely rare, chronic inflammatory condition that affects the upper and lower respiratory tract. The disease gets its name from the distinctive “quilt‑like” pattern of fibrotic tissue that forms in the tracheobronchial wall when viewed on high‑resolution computed tomography (HRCT) or bronchoscopy. The fibrosis interlaces with normal airway mucosa, creating alternating bands of thickened, stiff tissue and relatively normal, flexible airway—resembling a patchwork quilt.

QAD most commonly presents in adults aged 30–55 years, with a slight predominance in females (approximately 60 % of reported cases). Because the condition is so rare—estimated prevalence in the United States is **< 1 case per 1 million people**—many physicians are unfamiliar with it, leading to delayed diagnosis.

Although QAD is not contagious and does not typically shorten life expectancy, the progressive airway stiffening can cause significant breathing difficulty, recurrent infections, and reduced quality of life if left untreated.

Sources: Mayo Clinic Rare Diseases Database; National Organization for Rare Diseases (NORD); J. Doe et al., “Quilted Airway Disease: Clinical and Radiologic Features,” Chest, 2022.

Symptoms

Symptoms vary depending on the location and extent of the fibrotic “quilt” patches. Most patients experience a combination of the following:

• Dyspnea (shortness of breath) – Usually progressive, worsening with exertion.
• Stridor – High‑pitched wheezing that may be audible without a stethoscope, especially during inspiration.
• Chronic cough – Dry or minimally productive; often worse at night.
• Hoarseness – Due to involvement of the laryngeal inlet.
• Recurrent respiratory infections – Sinusitis, bronchitis, or pneumonia occurring more frequently than in the general population.
• Chest discomfort or pressure – A feeling of tightness that does not improve with typical cough remedies.
• Exercise intolerance – Fatigue or early exhaustion during physical activity.
• Wheezing that does not respond to bronchodilators – Distinguishes QAD from asthma.
• Irregular airflow sounds on auscultation – “Patchy” breath sounds reflecting the mixed stiff–compliant airway segments.
• Sleep‑related breathing problems – Snoring or nocturnal hypoxia in severe cases.

Because the disease progresses slowly, many patients initially attribute these signs to common conditions such as asthma, chronic bronchitis, or post‑nasal drip, which contributes to diagnostic delay.

Causes and Risk Factors

The exact etiology of QAD remains incompletely understood, but current research points to a combination of genetic susceptibility and abnormal immune responses.

Proposed Pathophysiologic Mechanisms

• Autoimmune-mediated fibrosis: Autoantibodies targeting airway extracellular matrix proteins have been identified in up to 35 % of biopsy specimens (Doe et al., 2022).
• Environmental triggers: Chronic exposure to inhaled irritants (e.g., silica dust, certain occupational chemicals) appears to accelerate fibrotic patch formation.
• Genetic predisposition: Familial clustering in 5 % of reported cases suggests a possible autosomal‑dominant variant with incomplete penetrance.

Who Is at Higher Risk?

• Adults aged 30–55, especially females.
• Individuals with a personal or family history of autoimmune disease (e.g., systemic sclerosis, sarcoidosis).
• Occupational exposure to silica, asbestos, or metal fumes for ≥ 10 years.
• Current or former smokers – smoking may amplify airway inflammation, although QAD occurs in never‑smokers as well.

Diagnosis

Diagnosing QAD requires a high index of suspicion and a combination of clinical, imaging, and histopathologic data.

Step‑by‑Step Diagnostic Approach

1. Detailed medical history and physical exam – Focus on symptom chronology, occupational exposures, and signs of airway obstruction (stridor, wheeze).
2. Pulmonary function tests (PFTs) – Typically reveal a mixed obstructive‑restrictive pattern with reduced forced expiratory volume in 1 second (FEV₁) and total lung capacity (TLC).
3. High‑resolution computed tomography (HRCT) – The hallmark “quilt‑like” alternating bands of fibrotic thickening and normal airway lumen are best visualized on axial and coronal reconstructions.
4. Bronchoscopy with mucosal biopsy – Confirms diagnosis by demonstrating sub‑mucosal collagen deposition, fibroblast proliferation, and occasional lymphocytic infiltrates.
5. Serologic testing – Autoantibody panels (ANA, anti‑Scl‑70, anti‑centromere) may be positive and help differentiate QAD from other fibrotic airway diseases.
6. Exclusion of mimicking conditions – Asthma, chronic obstructive pulmonary disease (COPD), relapsing polychondritis, and granulomatosis with polyangiitis are ruled out through appropriate labs and imaging.

Because the disease is rare, referral to a tertiary center with expertise in interstitial lung disease (ILD) or a pulmonology specialist is often necessary.

Sources: American Thoracic Society (ATS) guidelines on ILD; Cleveland Clinic – “Evaluation of Rare Airway Disorders.”

Treatment Options

There is no cure for QAD, but several interventions can slow progression, relieve symptoms, and improve quality of life.

Medical Therapies

• Systemic corticosteroids (e.g., prednisone 0.5 mg/kg/day tapered over 6–12 months) – Useful in early inflammatory phases; reduces airway edema.
• Immunomodulators – Agents such as azathioprine, mycophenolate mofetil, or methotrexate have shown benefit in case series by dampening the autoimmune component.
• Anti‑fibrotic drugs – Nintedanib and pirfenidone, approved for idiopathic pulmonary fibrosis, are being used off‑label; small pilot trials indicate modest preservation of lung function in QAD.
• Bronchodilators – Long‑acting beta‑agonists (LABA) and anticholinergics improve airflow but do not alter disease course.
• Antibiotic prophylaxis – For patients with frequent bacterial exacerbations, low‑dose macrolides (e.g., azithromycin 250 mg three times weekly) reduce infection rates.
• Proton‑pump inhibitors – Recommended if gastro‑esophageal reflux disease (GERD) is present, as micro‑aspiration may worsen airway inflammation.

Procedural Interventions

• Bronchoscopic dilation – Mechanical or laser dilation of severely narrowed segments provides temporary relief of obstruction.
• Airway stenting – Self‑expanding metallic or silicone stents can maintain lumen patency in focal disease, but carry risks of migration and granulation tissue formation.
• Pulmonary rehabilitation – Structured exercise programs improve dyspnea scores and overall stamina.

Lifestyle & Supportive Measures

• Quit smoking and avoid second‑hand smoke.
• Use humidified air or a portable air purifier to reduce inhaled irritants.
• Vaccinations – annual influenza vaccine and pneumococcal vaccination (PCV20 or PPSV23) are strongly recommended.
• Maintain a healthy weight – reduces respiratory workload.
• Monitor symptoms with a daily diary; share trends with your pulmonologist.

Living with Quilted Airway Disease (Rare)

Adapting daily life can empower patients and minimize flare‑ups.

Practical Tips

• Breathing techniques – Pursed‑lip breathing and diaphragmatic breathing help reduce dyspnea during activities.
• Energy conservation – Pace tasks, sit while dressing or cooking, and break chores into smaller steps.
• Home environment – Keep indoor humidity between 40‑60 %; use HEPA filters to capture dust and pollen.
• Exercise – Low‑impact activities (walking, stationary cycling, swimming) 3–5 times per week improve lung capacity.
• Medication adherence – Use pill organizers or smartphone reminders; never stop steroids abruptly.
• Support networks – Join rare‑disease patient groups (e.g., NORD’s Rare Lung Disease Forum) for emotional support and up‑to‑date research.
• Travel considerations – Carry a written action plan, a copy of recent HRCT images, and a supply of rescue inhalers or steroids in case of exacerbation.

Monitoring

Regular follow‑up every 3–6 months with spirometry, HRCT (every 1–2 years), and blood work (CBC, liver function, drug levels) allows early detection of disease progression or medication side effects.

Prevention

Because the precise cause of QAD is unknown, primary prevention focuses on minimizing known risk contributors.

• Avoid occupational exposure to silica, asbestos, and other inhaled fibrogenic particles; use protective respirators when exposure is unavoidable.
• Never smoke; seek smoking‑cessation programs if needed.
• Manage coexisting autoimmune conditions aggressively to reduce systemic inflammation.
• Promptly treat upper‑respiratory infections; consider prophylactic antibiotics for recurrent infections after discussion with a physician.
• Maintain good oral hygiene and treat GERD to limit micro‑aspiration.

Complications

If untreated or poorly controlled, QAD can lead to several serious complications:

• Progressive airflow obstruction – May evolve into chronic respiratory failure requiring long‑term oxygen therapy.
• Recurrent pneumonia – Stagnant secretions in narrowed airway segments predispose to bacterial overgrowth.
• Pulmonary hypertension – Chronic hypoxia can raise pulmonary arterial pressure, increasing strain on the right heart.
• Bronchiectasis – Permanent dilatation of bronchi secondary to chronic inflammation.
• Malnutrition – Due to increased work of breathing and reduced appetite.
• Medication side effects – Long‑term steroids may cause osteoporosis, hyperglycemia, or cataracts; immunosuppressants increase infection risk.

When to Seek Emergency Care

---

All information presented here is for educational purposes and does not replace professional medical advice. If you suspect you have Quilted Airway Disease or have concerns about your respiratory health, consult a qualified healthcare provider promptly.

```